Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age

K. Zaman, D. A. Sack, M. Yunus, S. E. Arifeen, G. Podder, T. Azim, S. Luby, R. F. Breiman, K. Neuzil, S. K. Datta, A. Delem, P. V. Suryakiran, H. L. Bock

Research output: Contribution to journalArticlepeer-review

Abstract

Co-administration of oral live-attenuated human rotavirus vaccine RIX4414 (Rotarix™) and oral polio vaccine (OPV) was assessed. Healthy infants were randomised to receive 2-doses of either: RIX4414 or placebo co-administered with OPV (12 and 16 weeks of age); or RIX4414 or placebo given 15 days after OPV. After vaccination, 56.5-66.7% of RIX4414 and 18.6% of placebo recipients had seroconverted for rotavirus IgA. No significant differences between RIX4414 groups with or without OPV co-administration were observed. No statistically significant differences were observed between groups for polio seroprotection rates. RIX4414 vaccine was immunogenic when co-administered with OPV and did not interfere with OPV seroprotection rates.

Original languageEnglish (US)
Pages (from-to)1333-1339
Number of pages7
JournalVaccine
Volume27
Issue number9
DOIs
StatePublished - Feb 25 2009
Externally publishedYes

Keywords

  • Gastrointestinal disease
  • Oral poliovirus
  • Rotavirus
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age'. Together they form a unique fingerprint.

Cite this